Efficacy of approved regimens in patients with early vs late relapse
| Clinical trial . | Study design . | Definition of FHR . | Patients, n . | Clinical outcomes . |
|---|---|---|---|---|
| POLLUX51 | DRd vs Rd | Early relapse: progression within 18 months from the start of first-line treatment Late relapse: progression after 18 months from the start of first-line treatment | Early relapse, 99 DRd arm, 47 Rd arm, 52 Late relapse, 196 DRd arm, 102 Rd arm, 94 | DRd vs Rd PFS, median Early relapse: 37 vs 12 mo (HR, 0.41; P = .0002) Late relapse: 69 vs 28 months (HR, 0.53; P = .0007) CR rates Early relapse: 53% vs 12% Late relapse: 62 vs 38% MRD rates (10−5) Early relapse: 30% vs 4% Late relapse: 34 vs 14% |
| ASPIRE52 | KRd vs Rd | Early relapse: progression within 12 months from the start of the prior treatment line Late relapse: progression after 12 months from the start of the prior treatment line | Early relapse, 217 KRd arm, 113 Rd arm, 104 Late relapse, 520 KRd arm, 263 Rd arm, 267 | KRd vs Rd PFS, median Early relapse: 21 vs 11 mo (HR, 0.7; P = .0026) Late relapse: 30 vs 18 mo (HR, 0.68; P = .0005) |
| CASTOR51 | DVd vs Vd | Early relapse: progression within 18 months from the start of first-line treatment Late relapse: progression after 18 months from the start of first-line treatment | Early relapse, 49 DVd arm, 30 Vd arm, 19 Late relapse, 186 DVd arm, 92 Vd arm, 94 | DVd vs Vd PFS, median Early relapse: 15 vs 9 mo (HR, 0.51, P = .048) Late relapse: 28 vs 8 mo (HR, 0.2; P > .0001) CR rates Early relapse: 21% vs 17% Late relapse: 51% vs 14% MRD rates (10−5) Early relapse: 13% vs 0% Late relapse: 23% vs 13% |
| ENDEAVOR52 | Kd vs Vd | Early relapse: progression within 12 months from the start of the prior treatment line Late relapse: progression after 12 months from the start of the prior treatment line | Early relapse, 239 Kd arm, 123 Vd arm, 116 Late relapse, 675 Kd arm, 335 Vd arm, 340 | Kd vs Vd PFS, median Early relapse: 14 vs 6 mo (HR, 0.6; P = .0017) Late relapse: 22 vs 10 mo (HR, 0.5; P < .0001) |
| CANDOR53 | DKd vs Kd | Early relapse: progression within 18 months from the start of first-line treatment Late relapse: progression after 18 months from the start of first-line treatment | Early relapse, 92 DKd arm, 59 Kd arm, 33 Late relapse, 118 DKd arm, 82 Kd arm, 36 | DKd vs Kd PFS, median Early relapse: NR vs 13 months (HR, 0.6) Late relapse: NR vs NR (HR, 0.7) CR rates Early relapse: 29% vs 3% Late relapse: 39% vs 17% |
| IKEMA54 | IsaKd vs Kd | Early relapse: progression within 18 months (1 prior line of therapy), 12 months (2 or more prior treatments), or 12 months from ASCT Late relapse: progression after 18 months (1 prior line of therapy), 12 months (2 or more prior treatments), or 12 months from ASCT | Early relapse, 107 IsaKd arm, 61 Kd arm, 46 Late relapse, 176 IsaKd arm, 104 Kd arm, 72 | Isakd vs Kd PFS, median Early relapse: 25 vs 17 mo (HR, 0.6) Late relapse: 43 vs 22 mo (HR, 0.5) MRD rates (10−5) Early relapse: 25% vs 15% Late relapse: 39% vs 17% |
| Clinical trial . | Study design . | Definition of FHR . | Patients, n . | Clinical outcomes . |
|---|---|---|---|---|
| POLLUX51 | DRd vs Rd | Early relapse: progression within 18 months from the start of first-line treatment Late relapse: progression after 18 months from the start of first-line treatment | Early relapse, 99 DRd arm, 47 Rd arm, 52 Late relapse, 196 DRd arm, 102 Rd arm, 94 | DRd vs Rd PFS, median Early relapse: 37 vs 12 mo (HR, 0.41; P = .0002) Late relapse: 69 vs 28 months (HR, 0.53; P = .0007) CR rates Early relapse: 53% vs 12% Late relapse: 62 vs 38% MRD rates (10−5) Early relapse: 30% vs 4% Late relapse: 34 vs 14% |
| ASPIRE52 | KRd vs Rd | Early relapse: progression within 12 months from the start of the prior treatment line Late relapse: progression after 12 months from the start of the prior treatment line | Early relapse, 217 KRd arm, 113 Rd arm, 104 Late relapse, 520 KRd arm, 263 Rd arm, 267 | KRd vs Rd PFS, median Early relapse: 21 vs 11 mo (HR, 0.7; P = .0026) Late relapse: 30 vs 18 mo (HR, 0.68; P = .0005) |
| CASTOR51 | DVd vs Vd | Early relapse: progression within 18 months from the start of first-line treatment Late relapse: progression after 18 months from the start of first-line treatment | Early relapse, 49 DVd arm, 30 Vd arm, 19 Late relapse, 186 DVd arm, 92 Vd arm, 94 | DVd vs Vd PFS, median Early relapse: 15 vs 9 mo (HR, 0.51, P = .048) Late relapse: 28 vs 8 mo (HR, 0.2; P > .0001) CR rates Early relapse: 21% vs 17% Late relapse: 51% vs 14% MRD rates (10−5) Early relapse: 13% vs 0% Late relapse: 23% vs 13% |
| ENDEAVOR52 | Kd vs Vd | Early relapse: progression within 12 months from the start of the prior treatment line Late relapse: progression after 12 months from the start of the prior treatment line | Early relapse, 239 Kd arm, 123 Vd arm, 116 Late relapse, 675 Kd arm, 335 Vd arm, 340 | Kd vs Vd PFS, median Early relapse: 14 vs 6 mo (HR, 0.6; P = .0017) Late relapse: 22 vs 10 mo (HR, 0.5; P < .0001) |
| CANDOR53 | DKd vs Kd | Early relapse: progression within 18 months from the start of first-line treatment Late relapse: progression after 18 months from the start of first-line treatment | Early relapse, 92 DKd arm, 59 Kd arm, 33 Late relapse, 118 DKd arm, 82 Kd arm, 36 | DKd vs Kd PFS, median Early relapse: NR vs 13 months (HR, 0.6) Late relapse: NR vs NR (HR, 0.7) CR rates Early relapse: 29% vs 3% Late relapse: 39% vs 17% |
| IKEMA54 | IsaKd vs Kd | Early relapse: progression within 18 months (1 prior line of therapy), 12 months (2 or more prior treatments), or 12 months from ASCT Late relapse: progression after 18 months (1 prior line of therapy), 12 months (2 or more prior treatments), or 12 months from ASCT | Early relapse, 107 IsaKd arm, 61 Kd arm, 46 Late relapse, 176 IsaKd arm, 104 Kd arm, 72 | Isakd vs Kd PFS, median Early relapse: 25 vs 17 mo (HR, 0.6) Late relapse: 43 vs 22 mo (HR, 0.5) MRD rates (10−5) Early relapse: 25% vs 15% Late relapse: 39% vs 17% |